Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · IEX Real-Time Price · USD
42.62
+0.30 (0.71%)
May 2, 2024, 9:34 AM EDT - Market open
Vera Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
51
Market Cap
2.32B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 0 | - | - |
| Dec 31, 2020 | 0 | - | - |
| Dec 31, 2019 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teladoc Health | 2.62B |
| Privia Health Group | 1.66B |
| CONMED | 1.26B |
| Guardant Health | 563.95M |
| Inari Medical | 520.66M |
| Denali Therapeutics | 330.53M |
| TG Therapeutics | 233.66M |
| Vericel | 197.52M |
VERA News
- 6 weeks ago - Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference - GlobeNewsWire
- 3 months ago - Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference - GlobeNewsWire
- 3 months ago - Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Class A Common Stock - GlobeNewsWire
- 3 months ago - Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock - GlobeNewsWire
- 3 months ago - Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - GlobeNewsWire
- 3 months ago - Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy - GlobeNewsWire
- 4 months ago - Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. - GlobeNewsWire